Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NDI-101150 |
Synonyms | |
Therapy Description |
NDI-101150 inhibits hematopoietic progenitor kinase 1 (HPK1; MAP4K1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NDI-101150 | NDI 101150|NDI101150 | MAP4K1 Inhibitor 7 | NDI-101150 inhibits hematopoietic progenitor kinase 1 (HPK1; MAP4K1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05128487 | Phase Ib/II | NDI-101150 NDI-101150 + Pembrolizumab | A Study of NDI 1150-101 in Patients With Solid Tumors | Recruiting | USA | 0 |